Hadassah

Placental Cells Mitigate Radiation-Induced Complications in Mice, Hadassah Researchers Reveal

Wednesday, Jun 26 2013

Placental cells, Hadassah Medical Organization researchers have shown, were successful in mitigating acute radiation-induced complications in mice when transplantation was initiated 24 hours following total body irradiation.

The research team from Hadassah's Biotechnology and Radiobiology Laboratory at the Sharett Institute of Oncology studied two types of placental cells--pure maternal cell preparations (PLX-Mat) and a mixture of maternal ¬and fetal derived cells (PLX-RAD), developed by Pluristem Therapeutics, a leading developer of placenta-based cell therapies. Using intramuscular (IM) injections, they were able to overcome the difficulty experienced by other researchers whereby, with intravenous treatment, the stem cells became trapped mostly in the lungs immediately after administration. Rather, IM injections enabled them to easily deliver higher numbers of cells through multiple injections at different times.

Twenty four hours and five days after total body irradiation, the mice were treated with placental stromal cells (PLX). The researchers discovered that PLX-Mat increased the survival of the irradiation mice from 27 percent to 68 percent, while PLX-RAD cells increased the survival to 98 percent. The researchers found that they could delay the treatment with PLX-RAD up to 48 hours after irradiation with similar success. The study showed that the treated mice regained their weight significantly faster than did the few control survivors. Furthermore, the treatment stimulated extensive hematopoietic (blood producing) stem cell proliferation, which enabled the speedy recovery of the radiation-induced depleted bone marrow with a parallel increase in the number of circulating white blood cells, red blood cells, and platelets.

The authors conclude: "Our study suggests that IM treatment with PLX-RAD cells may serve as a highly effective 'off the shelf' therapy to treat bone marrow failure following total body exposure to high doses of radiation." These cells can be stored, delivered frozen, and then defrosted just before injection.

The researchers add that they expect the treatment may also have major applications for clinical conditions associated with severe bone marrow aplasia, where blood cell development is impaired.

Read more here>>

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Jun 19 2018

American Journal of Ophthalmology Article Celebrates the Centennial of Hadassah Ophthalmology

The centennial anniversary of the Hadassah Medical Organization's Department of Ophthalmology is celebrated in the May issue of the American Journal of Ophthalmology, with an article by the immediate past director, Prof. Jacob Pe'er, and the current director, Prof. Itay Chowers.

READ MORE ›

Tuesday, Jun 12 2018

Hadassah Ophthalmology Department Research Highlighted by JAMA

Thanking the Hadassah Medical Organization’s researchers for their ”excellent submission” to JAMA Ophthalmology regarding a multi-center international study of the variable effectiveness of treatment for neovascular age-related macular degeneration (nAMD), the editors explained that their article was one of just a few from 12 JAMA on-line journals to be highlighted in The JAMA Network Reader this weekend.

READ MORE ›
alt_text

Monday, Jun 11 2018

Ruth Radiano: Passionate New Director of Nursing at Hadassah Hospital Mount Scopus

Translating her passion and professionalism into action, Ruth Radiano, the new Director of Nursing at Hadassah Hospital Mount Scopus, brings a background of 26 years of nursing at Hadassah.

READ MORE ›
alt_text

Thursday, Jun 7 2018

Former NYC Mayor Giuliani Calls Hadassah Hospital a Blessing

Former New York City Mayor Rudy Giuliani and his partner Dr. Maria Ryan, CEO of Cottage Hospital in Woodsville, New Hampshire visited Hadassah Medical Organization in Jerusalem today to get an update on Hadassah’s management of terror events.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More